CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 25 enrolled
Drug / intervention
nab-paclitaxel +2 moredrug
Likely dose
nab-paclitaxel 25 mg/m2from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01893801
NCT01893801Phase 2Completed
CompareCT.gov

A Phase 1b/2 Pilot Trial of Nab-Paclitaxel Plus Cisplatin Plus Gemcitabine (Nabplagem) in Patients With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma (PDA)

Pancreatic Cancer Research Team·interventional·Posted Jul 9, 2013·Updated May 29, 2019

In Brief

A Phase 2 clinical trial evaluating nab-paclitaxel, Cisplatin, and 1 other intervention for Stage IV Pancreatic Cancer. Completed, enrolled 25 participants across 3 sites.

Detailed Summary

The primary objective of this study is to determine the efficacy of nab-paclitaxel plus cisplatin plus gemcitabine for patients with metastatic pancreatic ductal adenocarcinoma (PDA).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsStage IV Pancreatic Cancer
CountriesUnited States
CollaboratorsTranslational Genomics Research Institute, Honor Health - Clinical Trials, Cancer Research and Biostatistics Clinical Trials Consortium

Timeline

Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedJul 9, 2013
Enrollment StartMay 1, 2013
Primary CompletionApr 1, 2016
Study CompletionOct 1, 2017
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 13.0 years ago

Interventions

nab-paclitaxeldrug

25 mg/m2 given intravenously (IV) on days 1 and 8 of a 21 day cycle

Cisplatindrug

25mg/m2 (or 50mg/m2) given intravenously (IV) on days 1 and 8 of a 21 day cycle

gemcitabinedrug

1000mg/m2 given intravenously (IV) on days 1 and 8 of a 21 day cycle